mipomersen

Genzyme is appealing because of its multiple sclerosis drug Campath, which could reach the market in 2012, plus a cholesterol lowering treatment, mipomersen, which is in late-stage clinical trials.

Genzyme rejects Sanofi-Aventis 'bear hug' 2010

The drug from Isis, called mipomersen, is in late-stage clinical testing.

Genzyme Boosts Pipeline 2008

SUNDAY, March 14 (HealthDay News) -- A new drug called mipomersen reduced low-density lipoprotein (LDL) "bad" cholesterol by nearly 25 percent when added to current therapy in people with a rare genetic condition that causes extremely high cholesterol, a new study finds.

Medlogs - Recent stories 2010

Carlsbad, Calif., drug-development company Isis Pharmaceuticals and large-cap biotechnology company Genzyme, based in Cambridge, Mass., said data from a late-stage study of mipomersen, which treats a rare genetic disorder that elevates patients 'cholesterol levels and puts them at higher risk for heart problems, met its primary endpoint.

P 600 Snaps 10-Day Winning Streak Kristina Peterson 2010

Carlsbad, Calif., drug-development company Isis Pharmaceuticals and large-cap biotechnology company Genzyme, based in Cambridge, Mass., said data from a late-stage study of mipomersen, which treats a rare genetic disorder that elevates patients 'cholesterol levels and puts them at higher risk for heart problems, met its primary endpoint.

P 600 Snaps 10-Day Winning Streak Kristina Peterson 2010

Carlsbad, Calif., drug-development company Isis Pharmaceuticals and large-cap biotechnology company Genzyme, based in Cambridge, Mass., said data from a late-stage study of mipomersen, which treats a rare genetic disorder that elevates patients 'cholesterol levels and puts them at higher risk for heart problems, met its primary endpoint.

P 600 Snaps 10-Day Winning Streak Kristina Peterson 2010

These are Campath for treating multiple sclerosis; mipomersen, in development with Isis Pharmaceuticals Inc. for a rare cholesterol-related disorder; and eliglustat, an oral treatment for Gaucher's disease.

Genzyme Plans Buyback, to Shed Businesses 2010

In this case, Mr. Crooke, disappointed with the market response after releasing the Phase III results of mipomersen back in May, upped the volume by saying mipomersen represents the third “remarkable” drug he has developed.

The Effusive CEO « CXO Footnotes 2009

Carlsbad, Calif. -based Isis Pharmaceuticals and large-cap Genzyme said their mipomersen drug cut bad cholesterol levels by 25% in a late-stage study of patients who have a rare genetic disorder.

AnnTaylor, Palm Fall; Tween Brands Soars 2009

In January, Isis licensed mipomersen to Genzyme, which will develop and commercialize it.

Isis and Genzyme Must Prove 2008